Entero Healthcare Q2 FY27 consolidated revenue at Rs 2,087.08 cr
Entero Healthcare Solutions Ltd reported consolidated revenue from operations of Rs 2,087.08 cr and profit after tax of Rs 60.74 cr for the quarter ended 30 September 2026, up from Rs 1,570.95 cr and
Key takeaways
- Revenue from operations: Rs 2,087.08 cr vs Rs 1,570.95 cr a year earlier
- Profit after tax: Rs 60.74 cr vs Rs 36.60 cr in the corresponding quarter
- Total income: Rs 2,091.07 cr vs Rs 1,575.74 cr year-on-year
- Total expenses: Rs 2,012.68 cr vs Rs 1,531.11 cr in Q2 FY26
- Basic EPS (Rs): 10.47 vs 7.26 in the same quarter last year
Q2 FY27 · consolidated
| Metric | Sep 2026 | Sep 2025 | Change |
|---|---|---|---|
| Revenue | Rs 2,087.08 cr | Rs 1,570.95 cr | +32.9% |
| PAT | Rs 60.74 cr | Rs 36.60 cr | +66.0% |
| EPS | Rs 10.47 | Rs 7.26 | +44.3% |
As reported in the filing. Figures are transcribed, not computed.
What the numbers show
-
Net margin was 2.91% of revenue, up 58 bps from 2.33%.
-
Revenue rose 32.9% while total expenses rose 31.5%.
-
Purchases of stock-in-trade accounted for Rs 467.95 cr of the Rs 481.57 cr rise in total expenses (97%).
-
Basis: Consolidated statement of unaudited financial results
-
Period reported: Quarter ended 30 September 2026 (Unaudited)
-
Prior period for comparison: Quarter ended 30 September 2025 (Unaudited)
-
Revenue from operations: Rs 2,087.08 cr (Q2 FY27) vs Rs 1,570.95 cr (Q2 FY26)
-
Other income: Rs 3.99 cr vs Rs 4.79 cr
-
Total income: Rs 2,091.07 cr vs Rs 1,575.74 cr
-
Purchase of stock-in-trade: Rs 1,866.28 cr vs Rs 1,398.33 cr
-
Changes in inventories of stock in trade: Rs (19.19) cr vs Rs 11.82 cr
-
Employee benefits expense: Rs 70.72 cr vs Rs 59.21 cr
-
Finance costs: Rs 23.14 cr vs Rs 12.40 cr
-
Depreciation and amortisation expense: Rs 13.13 cr vs Rs 9.83 cr
-
Other expenses: Rs 58.60 cr vs Rs 39.53 cr
-
Total expenses: Rs 2,012.68 cr vs Rs 1,531.11 cr
-
Profit before tax: Rs 78.39 cr vs Rs 44.62 cr
-
Total tax expenses: Rs 17.64 cr vs Rs 8.02 cr
-
Profit for the period (PAT): Rs 60.74 cr vs Rs 36.60 cr
-
Profit attributable to owners of the Company: Rs 45.54 cr vs Rs 31.60 cr
-
Profit attributable to non-controlling interests: Rs 15.20 cr vs Rs 5.00 cr
-
Total comprehensive income: Rs 62.80 cr vs Rs 36.18 cr
-
Basic EPS (Rs): Rs 10.47 vs Rs 7.26
-
Diluted EPS (Rs): Rs 10.45 vs Rs 7.25
According to the consolidated statement of unaudited financial results for the quarter ended 30 September 2026, revenue from operations increased to Rs 2,087.08 cr from Rs 1,570.95 cr in the corresponding quarter of the previous year. Total income, including other income, rose to Rs 2,091.07 cr from Rs 1,575.74 cr over the same period.
On the cost side, purchase of stock-in-trade moved up to Rs 1,866.28 cr from Rs 1,398.33 cr, while employee benefits expense increased to Rs 70.72 cr from Rs 59.21 cr. Finance costs were higher at Rs 23.14 cr compared with Rs 12.40 cr a year earlier, and depreciation and amortisation expense rose to Rs 13.13 cr from Rs 9.83 cr. Other expenses also increased to Rs 58.60 cr from Rs 39.53 cr. Total expenses for the quarter stood at Rs 2,012.68 cr versus Rs 1,531.11 cr in the corresponding prior period.
Profit before tax for the quarter was Rs 78.39 cr, up from Rs 44.62 cr in the year-ago quarter. After total tax expenses of Rs 17.64 cr (vs Rs 8.02 cr a year earlier), profit for the period (profit after tax) came in at Rs 60.74 cr, compared with Rs 36.60 cr in the same quarter of the previous year. Basic earnings per share, with a face value of Rs 10 each, were reported at Rs 10.47 versus Rs 7.26, while diluted earnings per share were Rs 10.45 versus Rs 7.25, as per the statement of financial results.
Track Entero Healthcare Solutions Ltd
Cruxal reads every Entero Healthcare Solutions Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Get every filing that moves a stock
One email before the open, with the day's filings that actually shifted a price — the number, the source document and what the market did with it. Free, and you can unsubscribe from any issue.
Cruxal publishes market coverage for information only. Nothing here is investment advice.